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Hepatitis C virus (HCV) is a leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma, as well as 
the most common indication for liver transplantation in many countries. Although the incidence of hepatitis C infection 
has dramatically decreased during the past decade, the worldwide reservoir of chronically infected persons is estimated 
at 170 million, or 3% of the global population. There is much controversy surrounding the natural history of hepatitis C 
infection. The rate of chronic HCV infection is affected by a person’s age, gender, race, and viral immune response.  
Approximately 75%-85% of HCV-infected persons will progress to chronic HCV infection, and are at risk for the 
development of extrahepatic manifestations, compensated and decompensated cirrhosis, and hepatocellular carcinoma 
(HCC). The rate of progression to cirrhosis is highly variable, and is influenced by several factors, including the amount 
of alcohol consumption, age of initial HCV infection, degree of inflammation and fibrosis on liver biopsy, HIV and HBV 
coinfection, and comordid conditions. An estimated 10%-15% of HCV-infected persons will advance to cirrhosis within 
the first 20 years. Persons with cirrhosis are at increased risk of developing HCC. An understanding of the natural 
history of hepatitis C is essential to effectively manage, treat, and counsel individuals with HCV infection. 
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1.  Introduction 
Chronic hepatitis C is the most common cause of 
chronic liver disease and cirrhosis, and the most common 
indication for liver transplantation in the United States 
(U.S.), Australia, and most of Europe.[1-3] Approximately 
170 million people are affected with HCV worldwide, 
comprising ~3% of the global population.[4] Hepatitis C 
virus (HCV) is the most common chronic bloodborne 
infection in the U.S., and is involved in 40% of chronic 
liver disease.[4, 5] HCV was initially isolated from the 
serum of a person with non-A, non-B hepatitis in 1989 by 
Choo et al.[6] Shortly after the cloning of HCV, this 
newfound virus was discovered to be the cause of 
approximately 90% of non-A, non-B hepatitis in the U.S.  
The hepatitis C virus is an RNA virus that belongs to 
the family flaviviridae.[7] HCV replicates in the cytoplasm 
of hepatocytes, but is not directly cytopathic. Persistent 
infection appears to rely on rapid production of virus and 
continuous cell-to-cell spread, along with a lack of 
vigorous T-cell immune response to HCV antigens. The 
HCV turnover rate can be quite high with replication 
ranging between 1010 to 1012 virions per day, and a 
predicted viral half-life of 2 to 3 hours.[8] The rapid viral 
replication and lack of error proofreading by the viral 
RNA polymerase are reasons why the HCV RNA genome 
mutates frequently.[9] There are six known genotypes 
(numbered 1 through 6) and more than 50 subtypes (e.g., 
1a, 1b, 2a...).[4] Frequent HCV mutations and numerous 
subtypes have made the search for an HCV vaccine 
challenging. 
There is strong evidence demonstrating the 
association of chronic HCV infection to cirrhosis and 
hepatocellular carcinoma (HCC). HCV is a mounting 
global health challenge, causing a significant proportion 
of chronic liver disease around the world. In 
understanding the long-term outcomes of HCV infection, 
clinicians may identify the patients at risk for HCV-related 
complications, and offer treatments to prevent further 
morbidity and mortality. 
2.  Routes of Transmission 
The transmission of HCV is primarily through 
exposure to infected blood. Risks for transmission include 
blood transfusion before 1992, intravenous drug use, high-
risk sexual activity, solid organ transplantation from an 
infected donor, occupational exposure, hemodialysis, 
household exposure, birth to an infected mother, and 
intranasal cocaine use. According to the U.S. Centers for 
Disease Control and Prevention (CDC), the most common 
risk factors for acute HCV infection in the U.S. from 1991-
1995 were high-risk drug (60%) and sexual behaviors 
(20%). Other modes of transmission (occupational, 
hemodialysis, household, and perinatal) accounted for 
approximately 10% of infections. A potential risk factor 
can be identified in approximately 90% of persons with 
HCV infection. In the remaining 10%, no recognized 
source of infection can be identified, although most 
persons in this category are associated with low 
socioeconomic level.[2] With current screening methods, 
HCV transmission through transfusion of contaminated 
blood products is approximately 1 in 500,000 to 2,000,000 
transfusions.[10-12]    
3.  Acute Hepatitis C 
In the U.S., the incidence of acute hepatitis C was 
estimated to be 180,000 cases per year in the mid-1980s 
(peak incidence), but declined to approximately 30,000 
new cases per year in 1995.[13] The incidence of acute 
hepatitis C infection in the U.S. declined sharply in 1990, 
possibly because of needle exchange programs and 
greater awareness of high risk HIV behavior.[5] Acute 
hepatitis C infection is infrequently diagnosed because the 
majority of acutely infected individuals are asymptomatic. Int. J. Med. Sci. 2006, 3  48
In the transfusion setting, where acute onset of HCV 
infection has been best documented, 70% to 80% of cases 
were asymptomatic.[14] About 20% to 30% of adults with 
acute HCV infection may develop clinical symptoms. The 
symptomatic onset ranges from 3 to 12 weeks after 
exposure.[15, 16] Symptoms may include malaise, 
weakness, anorexia, and jaundice. Serum alanine 
aminotransferase (ALT) levels, signifying hepatocyte 
necrosis, begin rising 2 to 8 weeks after exposure, and 
often reach levels of greater than 10 times the upper limits 
of normal. HCV RNA can be detected in the serum within 
1 to 2 weeks after exposure.[16, 17] The level of HCV RNA 
rises rapidly during the first few weeks, and then peaks 
between 105 to 107 IU/ml, shortly before the peak of 
serum aminotransferase levels and onset of symptoms. In 
self-limited acute hepatitis C, symptoms can last several 
weeks and subside as ALT and HCV RNA levels decline. 
Acute HCV infection can be severe, but fulminant liver 
failure is rare.[18] 
The antibody to HCV, as detected by enzyme 
immunoassay, becomes positive near the onset of 
symptoms, approximately 1 to 3 months after exposure. 
Up to 30% of patients will test negative for anti-HCV at 
onset of their symptoms, making anti-HCV testing 
unreliable in diagnosis of acute infection.[17] Almost all 
patients eventually develop the antibody to HCV; 
however, titers can be low or undetectable in 
immunodeficient patients. The anti-HCV assay detects 
greater than 90% of HCV infections after the initial 3 
months.  
4.  Chronic Hepatitis C 
Chronic hepatitis C is marked by the persistence of 
HCV RNA in the blood for at least 6 months after onset of 
acute infection. HCV is self-limiting in only 15%-25% of 
patients in whom HCV RNA in the serum becomes 
undetectable and ALT levels return to normal. 
Approximately 75%-85% of infected patients do not clear 
the virus by 6 months, and chronic hepatitis develops. The 
rate of chronic HCV infection is affected by many factors, 
including the age at time of infection, gender, ethnicity, 
and the development of jaundice during the acute 
infection (see Table 1). 
Table 1.  Risk Factors for Developing Chronic HCV Infection 
Risk Factors 
Age at time of infection > 25 years 
Male gender 
No jaundice or symptoms during acute infection 
African American race  
HIV infection 
Immunosuppression 
Age at Time of Infection 
The chronicity rate in hepatitis C infection appears to 
be lower in younger individuals. The most widely quoted 
data on the prevalence of HCV in the United States comes 
from the third National Health and Nutrition Examination 
Survey (NHANES), a national survey of a representative 
sample of non-institutionalized civilian Americans 
conducted between 1988 and 1994. In the NHANES study, 
the chronicity rate was estimated at 30% in subjects below 
the age of 20 years, and 76% for those older than 20 
years.[13] Long term follow-up studies in children with 
post-transfusion hepatitis indicate that only 55% to 60% of 
children remain HCV RNA positive in adulthood.[19] 
Studies of vertical transmission from mother to infant 
have suggested that a sizeable proportion of infants have 
transient infection and then clear the HCV RNA, 
sometimes without ever producing HCV antibodies.[20] 
In the Dionysos study from Italy, residents between the 
ages of 12 and 25 years had a chronicity rate of 56%, 
compared with 87% for those above the age of 25 
years.[21] The current data suggests that persons with 
HCV infection at younger age, less than 25 years, are less 
likely to have chronic hepatitis C than those infected at 
older ages. 
Gender 
The rate of chronicity in HCV infection appears to be 
lower in women, particularly younger women. Evidence 
for this comes mostly from retrospective analyses of two 
large outbreaks of hepatitis C that occurred among 
pregnant women who received Rh immune globulin that 
had been contaminated with HCV. In a 17-year follow-up 
study of 704 Irish women with anti-HCV after receipt of 
contaminated immune globulin, the chronicity rate was 
55%.[22] The same HCV chronicity rate (55%) was found 
in a 20-year follow-up study of 917 German women who 
had received a similarly HCV contaminated Rh immune 
globulin.[23] Conversely, large cross-sectional studies 
have not demonstrated gender differences in the rate of 
chronicity in hepatitis C infection. The  NHANES[13] 
study and the Dionysos study[21] had similar rates of 
HCV chronicity among both men and women. 
Race 
There are differences in the rate of chronic HCV 
infection, response to treatment, and development of 
complications, among different racial and ethnic groups 
with HCV infection. For unclear reasons, African 
Americans appear to have a higher rate of chronic HCV 
infection than Caucasians and Hispanic whites. In 
prospective surveys among inner-city Baltimore 
(Maryland, U.S.) injection drug users, the prevalence of 
chronic HCV infection in African American men was 
95%.[24, 25] The NHANES study also revealed a higher 
rate of chronic infection among African Americans (86%), 
compared to Caucasians (68%) (p=0.02). In addition, 
African American had a lower rate of sustained viral 
response (SVR) to interferon and ribavirin treatment for 
HCV infection.[26] Interestingly, African Americans and 
Asians with HCV have a 2-fold and 4-fold increased risk, 
respectively, of developing HCC when compared to 
Caucasians with HCV.[27]  No host or viral genetic 
differences have yet been identified to explain the racial 
disparities in the incidence of chronic HCV, response to 
treatment, or development of HCC. Clinical trials are 
currently ongoing in the U.S. to identify these factors.  
Jaundice and Immune Response 
The rate of chronic HCV infection is lower in patients 
who develop jaundice or symptoms during the acute 
onset of HCV infection as compared to those who are 
anicteric. In a prospective study of 142 HCV-infected 
subjects with a history of illicit drug use, subjects with 
viral clearance were more likely to have symptoms of 
jaundice (p=0.03).[25] Furthermore, the long-term follow-
up study of women infected with contaminated Rh 
immune globulin in Germany exhibited a rate of 
chronicity in 43% of those with history of jaundice, as 
compared to 60% among those who remained anicteric 
(p<0.001). Many have speculated that the jaundice may be 
associated with a more robust immune Th1 lymphocyte Int. J. Med. Sci. 2006, 3  49
and cytokine response to the HCV.[28, 29] The 
competency of the immune response plays a significant 
role in the development of chronic hepatitis C, as well as 
the progression of liver fibrosis. The rates of chronic HCV 
infection developing in patients with human 
immunodeficiency virus (HIV) infection and CD4 < 200, 
have been higher than in patients without HIV 
infection.[30]  
5.  Progression of Liver Fibrosis 
In the setting of persistent hepatitis C viremia, the 
rate of progression of liver fibrosis varies widely. There 
have been extensive studies focusing on the natural course 
of disease progression from chronic hepatitis C to 
cirrhosis, HCC, and death. The liver biopsy is the gold 
standard for the grading and staging of chronic hepatitis 
C. The activity of liver disease or grade, is gauged by the 
number of mononuclear inflammatory cells present in and 
around the portal areas, and by the number of dead or 
dying hepatocytes. The structural liver damage, also 
known as fibrosis or stage, is variable in chronic HCV 
infection. Fibrosis implies possible progression to 
cirrhosis. In mild cases, fibrosis is limited to the portal and 
periportal areas. More advanced changes are defined by 
fibrosis that extends from one portal area to another, also 
known as "bridging fibrosis.”  
Cirrhosis develops in approximately 10% to 15% of 
individuals with chronic HCV infection.[4] There are 
external and host factors that can increase the risk of 
progression of liver disease (see Table 2). Multiple studies 
have shown that chronic alcohol use is a major external 
risk factor for the progression of chronic hepatitis C to 
cirrhosis and HCC. Host risk factors include older age at 
time of infection, male gender, the degree of inflammation 
and fibrosis present on the liver biopsy, coinfection with 
human immunodeficiency virus (HIV) or hepatitis B virus 
(HBV), and comorbid conditions such as 
immunosuppression, insulin resistance, non-alcoholic 
steatohepatitis, hemochromatosis, and schistosomiasis.   
Table 2.  Risk Factors for Advanced Progression of Liver 
Fibrosis 
Risk Factors 
Alcohol consumption ( >30 g/day in males, >20  
g/day in females) 
Age at time of infection > 40 years 
Male gender 
Degree of inflammation and fibrosis on liver  
biopsy 
Coinfection with HIV or HBV 
Comorbid disease 
Alcohol consumption 
Alcohol consumption appears to be one of the most 
influential factors driving fibrosis progression in patients 
with chronic hepatitis C. There is convincing evidence that 
higher levels of alcohol consumption contributes to the 
development of progressive liver disease.[31-38] 
Individuals who consume alcohol as an ongoing habit 
have a greater prevalence of cirrhosis than those who 
consume little or no alcohol. The 2002 United States 
National Institutes of Health (NIH) Consensus Statement 
reports detrimental effects of 30 g/day in men (roughly 
equivalent to 3-4  12-ounce beers, 3-4  4-ounce glasses of 
wine, or 3 shots of a mixed drinks) and 20 g/day in 
women.[4] Lower amounts of daily alcohol consumption 
may also increase the risk of HCV-associated liver 
damage.  
Age at Time of Infection 
Several studies have shown a significant association 
between the rate of fibrosis and the age at time of 
infection.[38, 39] After controlling for the estimated 
duration of HCV infection, the stage of fibrosis was 
significantly higher in patients that were infected at an 
older age (>40 years), than those infected at younger 
ages.[38] The degree of inflammation and fibrosis on the 
liver biopsy has also been associated with further 
progression of HCV liver disease.[40] This data suggests 
that the progression of liver fibrosis in HCV infection is 
non-linear, and may develop at a faster rate as the patient 
ages. 
Coinfection with HIV and HBV 
HCV coinfections with HIV or HBV are significant 
risk factors for liver fibrosis. Coinfection with HCV and 
HIV is particularly common among hemophiliacs and 
injection drug users. HIV seropositivity and low CD4 
count appears to accelerate HCV liver fibrosis.[41-43] 
Conversely, HCV has been associated with a faster 
progression of HIV to acquired immunodeficiency 
syndrome (AIDS).[44]  Similarly, HCV coinfection with 
HBV also exhibits higher rates of progression to cirrhosis.  
Comorbid Conditions 
The role of comorbid conditions and HCV infection 
is an important component in the natural history of HCV 
infection. Immunosuppression has been associated with 
more aggressive liver disease. Patients with humoral 
immunoglobulin deficiency (hypogammaglobulinemic) or 
cellular immune impairment (organ transplant recipients) 
have shown significantly higher rates of progression to 
cirrhosis than immunocompetent patients.[42, 45, 46] 
Insulin resistance appears to be associated with worsening 
liver fibrosis and decreased response to HCV therapy.[47-
50] The relationship between HCV infection and comorbid 
conditions, such as non-alcoholic steatohepatitis, obesity, 
and insulin resistance are discussed in further detail in 
this issue of IJMS.  
6.  Long Term Complications 
Cirrhosis and HCC 
The progression to cirrhosis is often clinically silent, 
and some patients are not known to have hepatitis C until 
they present with the complications of end-stage liver 
disease or HCC. The features of decompensated cirrhosis 
include the development of ascites, upper gastrointestinal 
bleeding secondary to varices or portal hypertensive 
gastropathy, hepatorenal syndrome and hepatic 
encephalopathy. In the U.S., deaths associated with 
chronic HCV are more likely to be caused from 
decompensated cirrhosis rather than HCC. Studies have 
estimated the 3, 5, and 10-year survival rates of 
compensated cirrhosis to be 96%, 91%, and 79%, 
respectively.[51]. The cumulative probability of an 
episode of clinical decompensation is 5% at 1 year, and 
increases to 30% at 10 years from the diagnosis of 
cirrhosis.[51-53] Once decompensated cirrhosis occurs, the 
5-year survival rate falls to 50%.[51] The time from HCV 
infection to cirrhosis is dependent on multiple factors, and 
cannot be predicted in an individual patient. Virtually all 
HCV-related HCC occurs among patients with cirrhosis. 
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HCC was increased 17-fold in HCV-infected patients 
compared to HCV-negative controls.[54] The results of 
several retrospective trials show a moderate decrease in 
the risk of developing HCC among HCV patients treated 
with interferon.[55-58] This benefit appears to be greater 
in patients with a sustained viral  response rather than 
non-responders to interferon treatment.[59] 
Multiple studies have attempted to measure the time 
interval from infection to cirrhosis and HCC. Frequently, 
the initial time of infection is not known, and therefore 
must be estimated. On the other hand, individuals that 
contracted HCV through a single blood transfusion or 
surgery are able to provide more precise time intervals 
from infection to cirrhosis and HCC. In a longitudinal U.S. 
study by Tong et al., the mean time of development of 
cirrhosis was 21 +/- 10 years in chronic post-transfusion 
hepatitis C patients.[60] Although the mean time to 
cirrhosis in chronic HCV patients is estimated at 20 years, 
only 10-20% of patients will actually develop cirrhosis 
within this time period.[4, 61] In this same study by Tong 
et al., the time to diagnosis of HCC was 28 +/- 11 
years.[60] In a European study by Castells et al., the time 
to development of cirrhosis and HCC was 24 years and 27 
years, respectively.[62] Once cirrhosis is established, HCC 
develops at an annual rate of 1% to 4%.[52, 56, 57, 63-66] 
Higher estimates in the range of 5-7% have been reported 
from Japan. Given the close time range between cirrhosis 
and HCC, it is imperative to screen for HCC in HCV 
patients with cirrhosis. In the U.S., Australia, and Europe, 
liver transplantation is the principle long-term treatment 
for patients with severely decompensated cirrhosis 
and/or hepatocellular carcinoma.[3]  
7.  Extrahepatic Manifestations 
Chronic HCV infection has been associated with 
numerous extrahepatic manifestations. These 
manifestations can involve multiple organ systems, 
including renal, dermatologic, hematologic, and 
rheumatologic systems.[67, 68] Approximately 1%-2% of 
HCV-infected individuals will develop extrahepatic 
manifestations. The most common extrahepatic condition 
is mixed cryoglobulinemia. Cryoglobulins are found in 
50% of patients with chronic HCV infection. 
Cryoglobulinemia was found to be 11 times more frequent 
in a veterans HCV cohort group than their respective 
control population.[68] Only 25%-30% of HCV patients 
with mixed cryoglobulinemia develop clinical symptoms, 
ranging from fatigue, skin rashes, purpura, arthralgias, 
Raynaud’s phenomenon, vasculitis, renal disease, and 
peripheral neuropathies.[69] The clinical manifestations 
are thought to be caused by immune complex deposition 
in various organs. Severe symptoms from 
cryoglobulinemia appear to respond to interferon 
treatment, but relapse occurs frequently once treatment is 
discontinued.[70]  
Other frequent extrahepatic manifestations found in 
patient with chronic HCV infection are 
membranoproliferative glomerulonephritis, porphyria 
cutaneous tarda, lichen planus, and vitiligo. There is also 
some data that suggests an association between chronic 
HCV infection and non-Hodgkin’s and Hodgkin’s 
lymphoma, autoimmune thyroditis, Sjogren’s syndrome, 
and seronegative arthritis. It is unclear if these associated 
diseases are caused directly from HCV infection or from 
the underlying immune stimulation caused by chronic 
infection. 
8.  Summary 
The chronic nature of hepatitis C infection influences 
the clinical approach and management of this disease. 
Prevention of the HCV infection is possible by 
understanding the various mechanisms of viral 
transmission. Acute HCV infection is difficult to diagnose 
since 70%-80% of infected individuals are asymptomatic. 
Most infected persons are unaware of their exposure to 
HCV, and do not get diagnosed until many years later. 
The rate of chronic HCV infection is affected by the 
person’s age at time of infection, gender, race, and viral 
immune response.  A large proportion of HCV-infected 
persons, ranging from 75%-85%, develop chronic HCV 
infection, and are at risk for advanced liver fibrosis, HCV-
related extrahepatic complications, cirrhosis and HCC (see 
Figure 1). The rates of liver fibrosis progression is highly 
variable, and is influenced by the amount of alcohol 
consumption, age of initial HCV infection, degree of 
inflammation and fibrosis on liver biopsy, HIV or HBV 
coinfection, and comordid conditions. An estimated 10%-
20% of chronic HCV infections advance to end-stage liver 
disease over one or two decades. Extrahepatic 
manifestations can occur during chronic HCV infection or 
cirrhosis, but HCC appears to develop only after cirrhosis 
is established. Research is ongoing to determine the 
histological, biochemical, genetic and demographic 
markers that may further predict the outcome of HCV 
infections. 
Figure 1.  Natural History of HCV Infection 
 
9.  Future Research Direction 
There is a need for further research on HCV and the 
risk factors that lead to progression of fibrosis, cirrhosis, 
and HCC. Identification of additional viral, host, and 
external factors would help in developing means of 
prevention, early detection, and treatment. Although, 
many studies have examined the clinical course of HCV 
infection, long-term cohort studies are still needed to 
characterize the risk factor profiles that may predict the 
eventual outcome in chronic HCV infection, and to further 
define the outcome of patients with greater than 30 years 
of HCV infection. Since the response rates to our current 
HCV therapies are still variable, there is a necessity for 
innovative new therapies and vaccines. Importantly, our 
HCC screening and surveillance methods need to be 
evaluated to determine if they are effective in reducing 
morbidity and mortality in patients with cirrhosis. Int. J. Med. Sci. 2006, 3  51
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